Form 4: Carlsmed Chief IP Officer Acquires 44,977 RSUs

Carlsmed's Chief IP Officer and Director, Niall Casey, acquired 44,977 restricted stock units, increasing his beneficial ownership to 982,562 shares.

Summary

• Niall Casey, Chief IP Officer and Director of CARLSMED, INC. (CARL), acquired 44,977 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was January 28, 2026.
• Following this transaction, Niall Casey beneficially owns 982,562 shares of Common Stock.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest in three equal annual installments, with the first installment beginning on the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with long-term company performance, without indicating any immediate operational or financial changes.

Positives

• The grant of Restricted Stock Units (RSUs) aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and retention of key personnel like the Chief IP Officer.

Risks

• The value of the RSUs upon vesting is subject to market fluctuations of CARLSMED, INC.'s Common Stock.
• The RSUs are contingent rights and will only convert to actual shares if the vesting conditions (primarily continued employment over the vesting period) are met.

Future Outlook

The acquired Restricted Stock Units are subject to a three-year vesting schedule, with equal annual installments beginning on the first anniversary of the grant date (January 28, 2026). This indicates a future commitment and potential increase in Niall Casey's direct share ownership over the next three years.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) is a common form of equity compensation for executives and directors in the biotechnology and medical device industries. This practice is widely adopted by companies like Medtronic or Stryker to incentivize long-term performance and retain key talent by aligning their financial interests with shareholder value creation.

Comparison to Industry Standards

• The use of RSUs as a compensation mechanism is standard practice across the medical technology sector, comparable to how executives at companies like Zimmer Biomet or Intuitive Surgical receive equity grants.
• The three-year annual vesting schedule is a typical structure for RSU grants, designed to promote executive retention and long-term strategic focus, similar to compensation plans observed at peer companies.

Stakeholder Impact

• Shareholders: The grant of RSUs represents potential future dilution as shares are issued upon vesting, but it also strengthens management's alignment with shareholder interests.
• Employees (specifically Niall Casey): Provides a significant equity incentive, tying personal wealth directly to the company's stock performance and encouraging long-term commitment.

Next Steps

• The RSUs will vest in three equal annual installments, starting on January 28, 2027.
• Upon vesting, the RSUs will convert into shares of CARLSMED, INC. Common Stock.

Key Dates

Keywords

Carlsmed, CARL, Restricted Stock Units, RSU, Insider Transaction, Form 4, Executive Compensation, Niall Casey, Equity Grant